Alimentiv Inc.
Quick facts
Marketed products
- Mirikizumab (MIR) · Immunology / Gastroenterology
Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in immune-mediated diseases. - Treatment Algorithm A · Gastroenterology
Treatment Algorithm A is a clinical decision-support tool or protocol developed by Alimentiv Inc. for managing gastrointestinal or digestive conditions. - Treatment Algorithm B · Gastroenterology
Treatment Algorithm B is a clinical decision-support tool or therapeutic protocol developed by Alimentiv Inc. for gastrointestinal or digestive disorders. - Treatment Algorithm C
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Alimentiv Inc.
What are Alimentiv Inc.'s marketed drugs?
Top marketed products include Mirikizumab (MIR), Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C.
Related
- Mirikizumab (MIR) · Immunology / Gastroenterology
- Treatment Algorithm A · Gastroenterology
- Treatment Algorithm B · Gastroenterology
- Treatment Algorithm C
- Sector hub: All tracked pharma companies